Pregnancy claims
FDA will hold a public meeting March 30 on safety issues related to dietary supplement use during pregnancy. In a notice to be published in the Feb. 24 Federal Register, FDA seeks comments on five points: potential maternal and fetal hazards associated with supplement use for pregnancy-related conditions; existence of certain pregnancy-related conditions for which structure/function claims should be permitted; potential harm of using supplements during pregnancy for conditions unrelated to pregnancy; means of addressing safety concerns associated with supplement use during pregnancy; and use of specific warnings on supplements for pregnancy-related conditions. The meeting is 9 a.m. to 5 p.m. at the Hilton in Gaithersburg, Md.; comments are due within 60 days of the Federal Register notice date
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




